Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Finished Goods (2020 - 2025)

Bioventus (BVS) has disclosed Finished Goods for 6 consecutive years, with $61.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Finished Goods fell 13.33% year-over-year to $61.0 million, compared with a TTM value of $61.0 million through Dec 2025, down 13.33%, and an annual FY2025 reading of $61.0 million, down 13.33% over the prior year.
  • Finished Goods was $61.0 million for Q4 2025 at Bioventus, down from $74.4 million in the prior quarter.
  • Across five years, Finished Goods topped out at $75.0 million in Q3 2023 and bottomed at $31.5 million in Q3 2021.
  • Average Finished Goods over 5 years is $60.9 million, with a median of $65.9 million recorded in 2022.
  • The sharpest move saw Finished Goods skyrocketed 93.01% in 2021, then decreased 13.33% in 2025.
  • Year by year, Finished Goods stood at $50.8 million in 2021, then surged by 30.52% to $66.3 million in 2022, then grew by 5.97% to $70.3 million in 2023, then rose by 0.15% to $70.4 million in 2024, then decreased by 13.33% to $61.0 million in 2025.
  • Business Quant data shows Finished Goods for BVS at $61.0 million in Q4 2025, $74.4 million in Q3 2025, and $73.0 million in Q2 2025.